Although significant advances in screening and treatment , cervical cancer is the fifth most common female cancer in Europe. Major prognostic factors for oncological outcome are used to categorise patients at high, intermediate and low risk groups and to define the type of radical hysterectomy according "Querleu-Morrow classification". The goal of this prospective observational study is to evaluate the association between several inflammatory markers and risk groups according European guidelines in women with cervical cancer Human Papillomavirus (HPV)-associated, in order to optimize the treatment.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* At least 18-year-old patients.
* Patients histologically diagnosed with cervical cancer (squamous cell carcinoma or adenocarcinoma HPV- associated)
* Patients with (2018 FIGO) stage ≤ IB2 ("Early Cervical Cancer")
* Patients undergoing full-body CT-scan 30 days before enrollment.
Exclusion Criteria:
* Patients unfit to plead
* Patients with chronic inflammatory diseases (IBDs; rheumatic conditions)
* Synchronous tumors or cancer diagnosis in the previous 3 years
* Patients undergoing steroid therapy in the last 30 days prior to recruitment
Primary outcome measure(s)
Grading — 30 days after surgery Anatomic pathology report of cell anaplasia in the sampled tumor
Staging — 30 days after surgery Anatomic pathology report of extent to which the cancer has spread
Lymphovascular space invasion — 30 days after surgery Prognostic factor in cervical cancer
Histotype — 30 days after surgery Anatomic pathology report of tissue types of cancer
Tumor size — 30 days after surgery centimeters
Neutrophil-Lymphocyte Ratio (NLR) — 1 day previous surgery an absolute value obtained from the ratio of neutrophils to lymphocytes
Platelet-lymphocyte ratio(PLR) — 1 day previous surgery an absolute value obtained from the ratio of platelets to lymphocytes
Lymphocyte-monocyte Ratio (LMR) — 1 day previous surgery an absolute value obtained from the ratio of lymphocytes to monocytes
Trial sites (1)
Facility
City
Region
Status
Università degli Studi della Campania Luigi Vanvitelli
Naples
Naples
More University of Campania Luigi Vanvitelli trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.